IHE participates at ISPOR in Barcelona

IHE participates at the ISPOR (International Society for Pharmaeconomics and Outcomes Research) European congress in Barcelona 10-14 November.

On Monday 12th, IHE:s Ulf Persson will participate in the issue panel ‘Embracing the societal perspective for HTAs: will it become the new standard for reference case?

The poster  ‘Cost-effectiveness analysis of Ferric maltol (Feraccru®) versus Ferric Carboxymaltose (Ferinject®) for the treatment of iron deficiency anaemia in IBD patients in Sweden and Finland’, will be presented by IHE:s Jonas Hjelmgren and Oskar Ericson on November 12th.

On the morning of Tuesday the 13th, IHE:s Managing Director Peter Lindgren will participate in an educational symposium on the use of predictive modelling as a tool for reducing payer uncertainty.

The poster ‘Estimated events avoided and cost offsets associated with using canagliflozin to treat patients with or at high risk of developing symptomatic atherosclerotic cardiovascular disease (CVD) in England’, co-authored by IHE:s Michael Willis, Andreas Nilsson and Oskar Ericson, will be presented on November 13th.

If you want to meet with us you can e-mail Peter Lindgren (Managing Director), Ulf Persson (Senior Advisor) or Jonas Hjelmgren (Director Market Access).

See you in Barcelona!